Insights on scaling B2B revenue

Whether AEs should do their own prospecting depends entirely on deal size, stage, and how your pipeline is built. Getting it wrong in either direction is an expensive mistake - wasted capacity, or a pipeline that never reaches the volume you need.

A discount tied to a signature date rarely closes a deal - it just rewards buyers who were already coming. But you can use it to accelerate deals which are close if you really understand the situation.

Buying committees are getting larger, but most sellers still rely on a single contact. The gap isn't knowledge - every experienced seller knows multithreading matters. The problem is the small, human moments where the opportunity to build another relationship was visible and the seller let it pass.

Deals don't always die cleanly - they linger. When close dates keep slipping and champions go quiet, most pipelines are carrying losses that haven't been called yet. That distorts forecasts, wastes selling time, and masks the real coverage problem.

Proven product, real hospital deployments, strong supplier interest - and a CEO carrying every major commercial conversation alone. This is how MediShout moved from early traction to seven-figure ARR by fixing the commercial execution layer, not the product.

Most sales incentive plans fail not because the numbers are wrong, but because they're trying to do too much. One primary metric, tight management discipline, and genuine simplicity will outperform any cleverly engineered structure.